Fewer people to approve applications either means that the process slows down even more or corners get cut.
Take a guess at which of those options Musk likely prefers.
Neuralink in particular seems to have benefited from efforts to squash watchdogs.
The FDA, too, has been looking into similar issues.
In 2024, the FDA even gave Neuralink itsbreakthrough equipment designation, which allows for a speedier review process.
The only thing faster might be no review at all.
News from the future, delivered to your present.
